



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8-11

Evolving Trends in Return to Sport After Surgical Treatment of Osteochondral Lesions of the Talus A Systematic Review and Meta- analysis Up To 2024

L. Berveglieri, E. Cassanelli, T. Cerasoli, F. Gaiani, C.
Faldini, F. Vannini

Orthopedics and Traumatologic Clinic, Rizzoli IRCCS Orthopedic
Institute, Via Pupilli 1, Bologna 40136, Italy



Faculty Disclosure Information

- Nothing to disclosure
- No conflict of interest



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8–11

INTRODUCTION

- Among athletes, ankle traumas, such as severe sprains, are quite common.
- These traumatic events often damage both the articular **cartilage and the subchondral bone** leading to an osteochondral lesion of the talus (**OLT**).
- Up to **42% of professional soccer players** experiencing OLTs.
- **No consensus** on the most effective treatment, both for the general population and for athletes who require a swift return to pre-injury levels of performance.



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8–11

MATERIALS AND METHODS

- Systematic review on 3 large electronic **databases**



Scopus

Embase

- Exclusion Criteria**

| Exclusion Criteria | No. of Studies |
|--|----------------|
| No sport outcome | 305 |
| Less than 10 patients | 39 |
| Combination of treatment group/data not reported correctly | 53 |
| Language different from English | 36 |
| Patient overlap | 10 |
| Age < 18 | 5 |
| Total | 451 |

- Assessment of Methodological Quality: **MINORS** (Methodological Index for Non-Randomized Studies)
- Patient data:** number of ankles treated, **age**, **sex**, **stage of the defect and the lesion size**, whether the defect was **primary or secondary**, the mean **follow-up duration**, and the **reported OCD classification**
- Sport Outcome:** preoperative and post- operative mean values of the primary **sports-related outcomes**, Return to sport (**RTS**) at **any level** and return to the **pre-injury level**, mean **time** to RTS
- Preoperative and postoperative mean values of the **primary clinical score**



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8–11

RESULTS


- **80** studies
- **8 treatment groups** 
- 68 were non-comparative studies, with an average MINORS score of 9.7 (range, 3–15). 12 were comparative studies, with an average MINORS score of 15.9 (range, 11–22)
- **3155 OLTs (3106 patients)** was reviewed
- 63% of the patients were men, while 37% were women
- mean age at surgery of 34.5 ± 9.9 years
- mean body mass index of 25.7 ± 4.2 kg/m²
- mean lesion size of 111.5 ± 75.8 mm²
- mean follow-up of 4.7 ± 3.4 years

Table 2

Treatment groups included

| | No. of Surgical Strategies |
|--|----------------------------|
| Debridement | 2 |
| BMS (bone marrow stimulation) | 37 |
| BMS alone | 29 |
| BMS + pulsed electromagnetic field therapy | 3 |
| BMS + with platelet-rich plasma or mesenchymal stem cell injection | 5 |
| Fragment fixation | 4 |
| Retrograde drilling | 3 |
| Osteochondral replacement | 23 |
| Allograft | 3 |
| Osteochondral transplantation (OAT) | 14 |
| Autologous cancellous bone graft | 2 |
| Autologous osteoperiosteal transplantation | 4 |
| Chondrogenesis-inducing techniques | 12 |
| Bone marrow-derived cell transplantation (BMDCT) | 3 |
| Autologous matrix-induced chondrogenesis (AMIC) | 9 |
| Cartilage regeneration cell-based techniques | 8 |
| Autologous chondrocyte implantation (ACI) | 3 |
| Matrix-induced chondrocyte implantation (MACI) | 3 |
| Particulate juvenile cartilage transplantation (PJCT) | 2 |
| Metal resurfacing implant | 4 |
| Total | 93 |



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8–11

BONE MARROW STIMULATION

- **14** studies reported the **RTS rate**, including a total of **591** patients.
- Overall, **83.3%** (CI 95% 80.3%–86.2%) of them returned to sports regardless of the level.
- **9** studies reported the RTS at pre-injury level: among the 416, only **52.7%** (CI 95% 47.8–57.6) were able to return to their pre-injury level.
- In 8 studies, comprising a total of 329 patients, a mean **RTS time of 18.68 ± 8.50** weeks was calculated.

Table 3

Characteristics of the included patients for bone marrow stimulation group

| | |
|---|------------------|
| No. of Studies | 31 ^a |
| No. of patients (no. ankles) | 1606 (1621) |
| Age at surgery (29 studies, 1575 patients), years (mean ±SD) | 34.8 ± 10.3 |
| BMI (19 studies, 1139 patients), mean ±SD | 25.85 ± 4.27 |
| No. of lesions (224 patients), n (%) | |
| Primary | 201 (89.7) |
| Secondary | 23 (10.3) |
| Lesion size (21 studies, 1239 patients), mm ² , mean ±SD | 73.2 ± 37.5 |
| Study type | |
| Retrospective case series | 16 |
| Randomized controlled trial | 3 |
| Retrospective cohort studies | 3 |
| Prospective cohort studies | 1 |
| Retrospective comparative studies | 6 |
| Prospective comparative studies | 1 |
| Prospective case series | 1 |
| Final follow-up (29 studies, 1565 patients), mean ±SD | 4.8 ± 3.3 |
| Berndt and Harty classification (11 studies, 555 patients), n (%) | |
| Stage I | 175 (31.5) |
| Stage II | 175 (31.5) |
| Stage III | 144 (25.9) |
| Stage IV | 61 (11.1) |
| RTS rate (11 studies, 614 patients), mean (95% CI), % | 83.3 (80.3–86.2) |
| RTS to pre-injury level (n), mean (95% CI), % | 52.7 (47.8–57.6) |
| Time to RTS (9 studies, 329 patients), weeks (mean ±SD) | 18.68 ± 8.50 |



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8–11

CHONDROGENESIS-INDUCING TECHNIQUES (BONE MARROW-DERIVED CELL TRANSPLANTATION, AUTOLOGOUS MATRIX-INDUCED CHONDROGENESIS)

- **12 studies** involving patients with OLTs treated with chondrogenesis-inducing techniques were included, comprising a total of 452 patients (453 ankles) with a mean age of 34.8 ± 11.1 years.
- The mean follow-up was 4.69 ± 4.54 years.
- **5 studies** reported the **RTS rate** (3 BMDCT and 2 AMIC), involving a total of 191 patients. Among them, **79.6%** (CI 95% 73.8%–85.3%) returned to sports.
- The RTS to pre-injury level was detailed in only one study, as was the mean time to RTS, making pooling of these data impossible.

| Table 4 Characteristics of the included patients for chondrogenesis-inducing techniques | |
|--|------------------|
| No. studies | 12 ^a |
| No. Patients (No. ankles) | 452 (453) |
| Age at surgery (11 studies, 427 patients), mean ±SD | 34.8 ± 11.1 |
| BMI (8 studies, 310 patients), mean ±SD | 25.4 ± 4.6 |
| No. lesions, n (%) | |
| Primary | N/A |
| Secondary | |
| Lesion size (9 studies, 339 patients), mean ±SD | 158.3 ± 80.9 |
| Study type | |
| Retrospective case series | 7 |
| Randomized controlled trial | 1 |
| Retrospective comparative studies | 1 |
| Prospective case series | 3 |
| Final follow-up (12 studies, 452 patients), y, mean ±SD | 3.5 ± 0.9 |
| Berndt and Harty classification | N/A |
| RTS rate (5 studies, 232 patients), mean (95% CI), % | 79.6 (73.8–85.3) |
| RTS to pre-injury level (n), mean (95% CI), % | N/A |
| Time to RTS (No. patients), mean ±SD | N/A |

CARTILAGE REGENERATION CELL-BASED TECHNIQUES

(AUTOLOGOUS CHONDROCYTE IMPLANTATION, MATRIX-INDUCED CHONDROCYTE IMPLANTATION, PARTICULATE JUVENILE CARTILAGE TRANSPLANTATION)

- **8 studies**, encompassing a total of 173 patients (174 ankles) with a mean age of 31.8 ± 8.8 years. The mean follow-up was 3.8 ± 2.4 years
- **5 studies** reported the **RTS rate** (3 ACI and 2 MACI), with **70.7%** (95% CI 56.6– 92.9) of 123 patients (124 ankles) returning to sports at any level
- **4 studies** (94 patients, 95 ankles) reported a **return to pre-injury level** of **72.5%** (95% CI 55.9–94.4)

Table 5

Characteristics of the included patients for cartilage implantation

| | |
|--|------------------|
| No. studies | 8 ^a |
| No. patients (No. ankles) | 173 (174) |
| Age at surgery (7 studies, 149 patients), mean ±SD | 31.8 ± 8.8 |
| BMI (3 studies, 50 patients), mean ±SD | 26.9 ± 5.7 |
| No. lesions (7 studies, 161 patients), n (%) | |
| Primary | 88 (54.6) |
| Secondary | 73 (45.4) |
| Lesion size (8 studies, 173 patients), mm ² , mean ±SD | 197.2 ± 94.7 |
| Study type | |
| Retrospective case series | 3 |
| Retrospective comparative studies | 1 |
| Prospective case series | 4 |
| Final follow-up (8 studies, 173 patients), mean ±SD | 4.18 ± 1.68 |
| Berndt and Harty classification | N/A |
| RTS rate (5 studies, 123 patients), mean (95% CI), % | 70.7 (56.6–92.9) |
| RTS to pre-injury level (4 studies, 94 patients), mean (95% CI), % | 72.5 (55.9–94.4) |
| Time to RTS (No. patients), mean ±SD | N/A |

OSTEOCHONDRAL REPLACEMENT (OAT, ALLOGRAFT, AUTOLOGOUS OSTEOPERIOSTEAL TRANSPLANTATION)

- **21 studies**, encompassing a total of 620 patients (629 ankles) with a mean age of 26.17 \pm 0.89 years
- **11 studies** reported the RTS rate
- Among them, **83.7%** (CI 95% 79.6%–87.8%) returned to sports at **any level**
- However, only **54.6%** (CI 95% 45.6%–63.6%) of patients were able to return to their **pre-injury level** (7 studies, 160 patients, 161 ankles)
- In **3 studies** (116 patients, 117 ankles), a mean RTS time of **34.8 \pm 33.9 weeks** was calculated

| Table 6 Characteristics of the included patients for osteo(chondral) transplantation | |
|---|-----------------------|
| No. Studies | 21^a |
| No. patients (No. ankles) | 620 (629) |
| Age at surgery (608 patients), mean \pm SD | 35.9 \pm 6.1 |
| BMI (323 patients), mean \pm SD | 26.17 \pm 0.89 |
| No. lesions (125 patients), n (%) | |
| Primary | 67 (53.6) |
| Secondary | 56 (46.4) |
| Lesion size (358 patients), mm ² , mean \pm SD | 160.1 \pm 78.1 |
| Study type | |
| Retrospective case series | 15 |
| Retrospective cohort studies | 1 |
| Retrospective comparative studies | 1 |
| Prospective case series | 4 |
| Final follow-up (21 studies, 620 patients), y, mean \pm SD | 4.69 \pm 4.54 |
| Berndt and Harty classification (3 studies, 43 patients) | |
| Stage I | 0 (0) |
| Stage II | 4 (9) |
| Stage III | 19 (44) |
| Stage IV | 20 (47) |
| RTS rate (11 studies, 364 patients), mean (95% CI), % | 83.7 (79.6–87.8) |
| RTS to pre-injury level (7 studies, 160 patients), mean (95% CI), % | 54.6 (45.6–63.6) |
| Time to RTS (3 studies, 116 patients), mean \pm SD | 34.8 \pm 33.9 |

OTHER TREATMENT

- **ARTHROSCOPIC DEBRIDEMENT:** ONLY 2 STUDIES, 22 ANKLES, RTS WAS 95.8% (95% CI 91.3%–100%) RATE, RTS at the pre-injury level was 86.3% (95% CI 80.2%–100%) rate
- **RETROGRADE DRILLING:** 3 studies, 66 patients (66 ankles), only one study reported the RTS value, making pooling of data impossible
- **FRAGMENT FIXATION:** 4 studies, 89 patients (91 ankles), RTS was 84.0% (CI 95% 73.8–94.2) of the patients returning to sports at any level. None of the studies reported the RTS to the pre- injury level or RTS time
- **METAL IMPLANTS:** 2 studies reported an RTS rate, 43 patients, 60.5% (CI 95% 45.8%–75.1%) returned to sports at any level, 41.9% (CI 95% 27.1%–56.6%) were able to return to their pre-injury level. In 3 studies (68 patients), a mean RTS time was 17.4 +- 0.5 weeks



CONCLUSION

- The various surgical treatment options available for talar OCD offer adequate RTS times and rates. However, **RTS rates decrease when considering patients' return to their pre-injury levels.**
- The high number of studies on BMS methods demonstrates that these techniques are often the first choice for treating osteochondral lesions of the talus. Despite this, the **RTS to pre-injury level appears to be statistically lower compared to other methods.**
- **Regenerative cell-based techniques**, while permitting a slower RTS, achieve a higher percentage of **RTS at pre-injury level (72%).**
- **Osteochondral replacement**, on the other hand, has a high rate of RTS and an RTS at pre-injury level that is lower than regenerative cell-based techniques but superior to BMS.
- Nonetheless, given the poor quality of the included studies and the low number of studies in each subgroup reporting sports-related parameters, it is currently not possible to define a superior treatment.
- A **tailored approach** for each individual case should be pursued to ensure an adequate RTS for the athlete without compromising long-term clinical outcomes.



REFERENCES


1. Saxena A, Eakin C. Articular talar injuries in athletes: results of microfracture and autogenous bone graft. *Am J Sports Med* 2007;35(10):1680–7.
2. Murawski CD, Jamal MS, Hurley ET, et al. Terminology for osteochondral lesions of the ankle: proceedings of the international consensus meeting on cartilage repair of the ankle. *J ISAKOS* 2022;7(2):62–6.
3. D'Hooghe P, Murawski CD, Boakye LAT, et al. Rehabilitation and return to sports: proceedings of the international consensus meeting on cartilage repair of the ankle. *Foot Ankle Int* 2018;39(1_suppl). 61S-7S.
4. Krause F, Anwander H. Osteochondral lesion of the talus: still a problem? *EFORT Open Rev* 2022;7(6):337–43.
5. Bezuglov E, Khaitin V, Lazarev A, et al. Asymptomatic foot and ankle abnormalities in elite professional soccer players. *Orthop J Sports Med* 2021;9(1):2325967120979994.
6. Buck TMF, Lauf K, Dahmen J, et al. Non-operative management for osteochondral lesions of the talus: a systematic review of treatment modalities, clinical- and radiological outcomes. *Knee Surg Sports Traumatol Arthrosc* 2023;31(8):3517–27.
7. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.
8. Savva N, Jabur M, Davies M, et al. Osteochondral lesions of the talus: results of repeat arthroscopic debridement. *Foot Ankle Int* 2007;28(6):669–73.
9. Sheu C, Ferkel RD. Athletic performance in the National Basketball Association after arthroscopic debridement of osteochondral lesions of the talus. *Orthop J Sports Med* 2021;9(1):2325967120970205.
10. Shapiro F, Koide S, Glimcher MJ. Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 1993;75(4):532–53.
11. Choi JI, Lee KB. Comparison of clinical outcomes between arthroscopic subchondral drilling and microfracture for osteochondral lesions of the talus. *Knee Surg Sports Traumatol Arthrosc* 2016;24(7):2140–7.
12. Rosenberger RE, Fink C, Bale RJ, et al. Computer-assisted minimally invasive treatment of osteochondrosis dissecans of the talus. *Operat Orthop Traumatol* 2006;18(4):300–16.
13. Wu X, Zhong Y, Wei S, et al. Retrograde drilling and bone graft for hepple stage v subchondral bone lesion of talus using 3d image-based navigation-assisted endoscopic technique. *Foot Ankle Int* 2023;44(10):1003–12.
14. Kumai T, Takakura Y, Kitada C, et al. Fixation of osteochondral lesions of the talus using cortical bone pegs. *J Bone Joint Surg Br* 2002;84(3):369–74.
15. Lambers KTA, Dahmen J, Reilingh ML, et al. Arthroscopic lift, drill, fill and fix (LDFF) is an effective treatment option for primary talar osteochondral defects. *Knee Surg Sports Traumatol Arthrosc* 2020;28(1):141–7.
16. Park CH, Song KS, Kim JR, et al. Retrospective evaluation of outcomes of bone peg fixation for osteochondral lesion of the talus. *Bone Joint Lett J* 2020;102-B(10):1349–53.
17. Sawa M, Nakasa T, Ikuta Y, et al. Outcome of autologous bone grafting with preservation of articular cartilage to treat osteochondral lesions of the talus with large associated subchondral cysts. *Bone Joint Lett J* 2018;100-B(5):590–5.
18. Ebskov LB, Hegnet Andersen K, Bro Rasmussen P, et al. Mid-term results after treatment of complex talus osteochondral defects with HemiCAP implantation. *Foot Ankle Surg* 2020;26(4):384–90.
19. Ettinger S, Stukenborg-Colsman C, Waizy H, et al. Results of HemiCAP((R)) implantation as a salvage procedure for osteochondral lesions of the talus. *J Foot Ankle Surg* 2017;56(4):788–92.
20. van Bergen CJ, van Eekeren IC, Reilingh ML, et al. Treatment of osteochondral defects of the talus with a metal resurfacing inlay implant after failed previous surgery: a prospective study. *Bone Joint Lett J* 2013;95-B(12):1650–5.
21. Vuurberg G, Reilingh ML, van Bergen CJA, et al. Metal resurfacing inlay implant for osteochondral talar defects after failed previous surgery: a midterm prospective follow-up study. *Am J Sports Med* 2018;46(7):1685–92.
22. Steman JAH, Dahmen J, Lambers KTA, et al. Return to sports after surgical treatment of osteochondral defects of the talus: a systematic review of 2347 cases. *Orthop J Sports Med* 2019;7(10):2325967119876238.
23. Vreeken JT, Dahmen J, Stornebrink T, et al. Second-look arthroscopy shows inferior cartilage after bone marrow stimulation compared with other operative techniques for osteochondral lesions of the talus: a systematic review and meta-analysis. *Cartilage* 2024;19476035241227332.
24. van Eekeren IC, van Bergen CJ, Sierevelt IN, et al. Return to sports after arthroscopic debridement and bone marrow stimulation of osteochondral talar defects: a 5- to 24-year follow-up study. *Knee Surg Sports Traumatol Arthrosc* 2016;24(4):1311–5.
25. Viglione V, Berveglieri L, Filardo G, et al. Autologous chondrocyte implantation for the treatment of osteochondral lesions of the talus: What happens after 20 years? *Foot Ankle Surg* 2024;30(7):546–51.
26. Shimozono Y, Seow D, Yasui Y, et al. Knee-to-talus donor-site morbidity following autologous osteochondral transplantation: a meta-analysis with best-case and worst-case analysis. *Clin Orthop Relat Res* 2019;477(8):1915–31.
27. Lee M, Kwon JW, Choi WJ, et al. Comparison of outcomes for osteochondral lesions of the talus with and without chronic lateral ankle instability. *Foot Ankle Int* 2015;36(9):1050–7.
28. Giannini S, Buda R, Faldini C, et al. Surgical treatment of osteochondral lesions of the talus in young active patients. *J Bone Joint Surg Am* 2005;87(Suppl 2):28–41.
29. Allahabadi S, Johnson B, Whitney M, et al. Short-term outcomes following dehydrated micronized allogenic cartilage versus isolated microfracture for treatment of medial talar osteochondral lesions. *Foot Ankle Surg* 2022;28(5):642–9.
30. Bonnin M, Bouysset M. Arthroscopy of the ankle: analysis of results and indications on a series of 75 cases. *Foot Ankle Int* 1999;20(11):744–51.
31. Choi SW, Lee GW, Lee KB. Arthroscopic microfracture for osteochondral lesions of the talus: functional outcomes at a mean of 6.7 years in 165 consecutive ankles. *Am J Sports Med* 2020;48(1):153–8.
32. Corr D, Raikin J, O'Neil J, et al. Long-term outcomes of microfracture for treatment of osteochondral lesions of the talus. *Foot Ankle Int* 2021;42(7):833–40.
33. Dogar F, Uzun E, Gurbuz K, et al. Comparison of arthroscopic treatment methods in talar osteochondral lesions: a multicenter, prospective, randomized clinical trial. *J Am Podiatr Med Assoc* 2021;111(4).
34. Domayer SE, Welsch GH, Stelzeneder D, et al. Microfracture in the ankle: clinical results and mri with t2-mapping at 3.0 t after 1 to 8 years. *Cartilage* 2011;2(1):73–80.
35. Draper SD, Fallat LM. Autogenous bone grafting for the treatment of talar dome lesions. *J Foot Ankle Surg* 2000;39(1):15–23.
36. Ferkel RD, Zanotti RM, Komenda GA, et al. Arthroscopic treatment of chronic osteochondral lesions of the talus: long-term results. *Am J Sports Med* 2008;36(9):1750–62.
37. Guney A, Akar M, Karaman I, et al. Clinical outcomes of platelet rich plasma (PRP) as an adjunct to microfracture surgery in osteochondral lesions of the talus. *Knee Surg Sports Traumatol Arthrosc* 2015;23(8):2384–9.
38. Kim YS, Park EH, Kim YC, et al. Clinical outcomes of mesenchymal stem cell injection with arthroscopic treatment in older patients with osteochondral lesions of the talus. *Am J Sports Med* 2013;41(5):1090–9.
39. Lambers KTA, Dahmen J, Altink JN, et al. Bone marrow stimulation for talar osteochondral lesions at long-term follow-up shows a high sports participation though a decrease in clinical outcomes over time. *Knee Surg Sports Traumatol Arthrosc* 2021;29(5):1562–9.
40. Lee KB, Bai LB, Chung JY, et al. Arthroscopic microfracture for osteochondral lesions of the talus. *Knee Surg Sports Traumatol Arthrosc* 2010;18(2):247–53.
41. Lee KB, Park HW, Cho HJ, et al. Comparison of arthroscopic microfracture for osteochondral lesions of the talus with and without subchondral cyst. *Am J Sports Med* 2015;43(8):1951–6.
42. Lee KT, Song SY, Hyuk J, et al. Lesion size may predict return to play in young elite athletes undergoing microfracture for osteochondral lesions of the talus. *Arthroscopy* 2021;37(5):1612–9.
43. Murphy EP, McGoldrick NP, Curtin M, et al. A prospective evaluation of bone marrow aspirate concentrate and microfracture in the treatment of osteochondral lesions of the talus. *Foot Ankle Surg* 2019;25(4):441–8.
44. Ogilvie-Harris DJ, Sarrosa EA. Arthroscopic treatment of osteochondritis dissecans of the talus. *Arthroscopy* 1999;15(8):805–8.
45. Park HW, Lee KB. Comparison of chondral versus osteochondral lesions of the talus after arthroscopic microfracture. *Knee Surg Sports Traumatol Arthrosc* 2015;23(3):860–7.
46. Reilingh ML, van Bergen CJ, Blankevoort L, et al. Computed tomography analysis of osteochondral defects of the talus after arthroscopic debridement and microfracture. *Knee Surg Sports Traumatol Arthrosc* 2016;24(4):1286–92.
47. Reilingh ML, van Bergen CJ, Gerards RM, et al. Effects of pulsed electromagnetic fields on return to sports after arthroscopic debridement and microfracture of osteochondral talar defects: a randomized, double-blind, placebo-controlled, multicenter trial. *Am J Sports Med* 2016;44(5):1292–300.
48. Schuman L, Struijs PA, van Dijk CN. Arthroscopic treatment for osteochondral defects of the talus. Results at follow-up at 2 to 11 years. *J Bone Joint Surg Br* 2002;84(3):364–8.
49. Schwartz AM, Niu S, Mirza FA, et al. Surgical treatment of talus OCL: mid- to long-term clinical outcome with detailed analyses of return to sport. *J Foot Ankle Surg* 2021;60(6):1188–92.
50. Seijas R, Alvarez P, Ares O, et al. Osteocartilaginous lesions of the talus in soccer players. *Arch Orthop Trauma Surg* 2010;130(3):329–33.
51. Shimozono Y, Williamson ERC, Mercer NP, et al. Use of extracellular matrix cartilage allograft may improve infill of the defects in bone marrow stimulation for osteochondral lesions of the talus. *Arthroscopy* 2021;37(7):2262–9.
52. van Bergen CJ, Kox LS, Maas M, et al. Arthroscopic treatment of osteochondral defects of the talus: outcomes at eight to twenty years of follow-up. *J Bone Joint Surg Am* 2013;95(6):519–25.
53. Ventura A, Terzaghi C, Legnani C, et al. Treatment of post-traumatic osteochondral lesions of the talus: a four-step approach. *Knee Surg Sports Traumatol Arthrosc* 2013;21(6):1245–50.



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8–11



REFERENCES

54. Wei M, Wei Y, Liu Y. Effects of early weightbearing on microfracture treatment of osteochondral lesions of talus with subchondral bone defects. *Curr Med Sci* 2019;39(1):88–93.
55. Yang HY, Lee KB. Arthroscopic microfracture for osteochondral lesions of the talus: second-look arthroscopic and magnetic resonance analysis of cartilage repair tissue outcomes. *J Bone Joint Surg Am* 2020;102(1):10–20.
56. Ackermann J, Casari FA, Germann C, et al. Autologous matrix-induced chondrogenesis with lateral ligament stabilization for osteochondral lesions of the talus in patients with ankle instability. *Orthop J Sports Med* 2021;9(5):23259671211007439.
57. Ahmad J, Maltenfort M. Arthroscopic treatment of osteochondral lesions of the talus with allograft cartilage matrix. *Foot Ankle Int* 2017;38(8):855–62.
58. Casari FA, Germann C, Weigelt L, et al. The role of magnetic resonance imaging in autologous matrix-induced chondrogenesis for osteochondral lesions of the talus: analyzing MOCART 1 and 2.0. *Cartilage* 2021;13(1_suppl): 639S–45S.
59. D'Ambrosi R, Villafane JH, Indino C, et al. Return to sport after arthroscopic autologous matrix-induced chondrogenesis for patients with osteochondral lesion of the talus. *Clin J Sport Med* 2019;29(6):470–5.
60. Efrima B, Barbero A, Maccario C, et al. Significant clinical improvement after arthroscopic autologous matrix-induced chondrogenesis for osteochondral lesions of the talus: a 5-year follow-up. *Cartilage* 2024;19476035241240341.
61. Kubosch EJ, Erdle B, Izadpanah K, et al. Clinical outcome and T2 assessment following autologous matrix-induced chondrogenesis in osteochondral lesions of the talus. *Int Orthop* 2016;40(1):65–71.
62. Richter M, Zech S. Matrix-associated stem cell transplantation (MAST) in chondral defects of foot and ankle is effective. *Foot Ankle Surg* 2013;19(2):84–90.
63. Sadlik B, Kolodziej L, Puzkarz M, et al. Surgical repair of osteochondral lesions of the talus using biologic inlay osteochondral reconstruction: clinical outcomes after treatment using a medial malleolar osteotomy approach compared to an arthroscopically-assisted approach. *Foot Ankle Surg* 2019;25(4):449–56.
64. Vannini F, Cavallo M, Ramponi L, et al. Return to sports after bone marrow-derived cell transplantation for osteochondral lesions of the talus. *Cartilage* 2017;8(1):80–7.
65. Weigelt L, Hartmann R, Pfirrmann C, et al. Autologous matrix-induced chondrogenesis for osteochondral lesions of the talus: a clinical and radiological 2- to 8-year follow-up study. *Am J Sports Med* 2019;47(7):1679–86.
66. Anders S, Goetz J, Schubert T, et al. Treatment of deep articular talus lesions by matrix associated autologous chondrocyte implantation—results at five years. *Int Orthop* 2012;36(11):2279–85.
67. Aurich M, Bedi HS, Smith PJ, et al. Arthroscopic treatment of osteochondral lesions of the ankle with matrix-associated chondrocyte implantation: early clinical and magnetic resonance imaging results. *Am J Sports Med* 2011;39(2):311–9.
68. Baums MH, Heidrich G, Schultz W, et al. Autologous chondrocyte transplantation for treating cartilage defects of the talus. *J Bone Joint Surg Am* 2006;88(2):303–8.
69. Buda R, Vannini F, Castagnini F, et al. Regenerative treatment in osteochondral lesions of the talus: autologous chondrocyte implantation versus one-step bone marrow derived cells transplantation. *Int Orthop* 2015;39(5):893–900.
70. Dekker TJ, Steele JR, Federer AE, et al. Efficacy of particulated juvenile cartilage allograft transplantation for osteochondral lesions of the talus. *Foot Ankle Int* 2018;39(3):278–83.
71. Kwak SK, Kern BS, Ferkel RD, et al. Autologous chondrocyte implantation of the ankle: 2- to 10-year results. *Am J Sports Med* 2014;42(9):2156–64.
72. Lopez-Alcorocho JM, Guillen-Vicente I, Rodriguez-Inigo E, et al. High-density autologous chondrocyte implantation as treatment for ankle osteochondral defects. *Cartilage* 2021;12(3):307–19.
73. Manzi J, Arzani A, Hamula MJ, et al. Long-term patient-reported outcome measures following articulated juvenile allograft cartilage implantation for treatment of difficult osteochondral lesions of the talus. *Foot Ankle Int* 2021;42(11): 1399–409.
74. Dahmen J, Rikken Q, Stufkens SAS, et al. Talar osteoperiostic grafting from the iliac crest (TOPIC): two-year prospective results of a novel press-fit surgical technique for large, complex osteochondral lesions of the medial talus. *J Bone Joint Surg Am* 2023;105(17):1318–28.
75. Fiske JW, Dalal AH, McCauley JC, et al. Participation in sports or recreational activities after osteochondral allograft transplantation of the talus. *Am J Sports Med* 2024;52(5):1258–64.
76. Gautier E, Kolker D, Jakob RP. Treatment of cartilage defects of the talus by autologous osteochondral grafts. *J Bone Joint Surg Br* 2002;84(2):237–44.
77. Haasper C, Zelle BA, Knobloch K, et al. No mid-term difference in mosaicplasty in previously treated versus previously untreated patients with osteochondral lesions of the talus. *Arch Orthop Trauma Surg* 2008;128(5):499–504.
78. Hintermann B, Wagnen J, Knupp M, et al. Treatment of extended osteochondral lesions of the talus with a free vascularised bone graft from the medial condyle of the femur. *Bone Joint Lett J* 2015;97-B(9):1242–9.
79. Hu Y, Guo Q, Jiao C, et al. Treatment of large cystic medial osteochondral lesions of the talus with autologous osteoperiosteal cylinder grafts. *Arthroscopy* 2013; 29(8):1372–9.
80. Imhoff AB, Paul J, Ottinger B, et al. Osteochondral transplantation of the talus: long-term clinical and magnetic resonance imaging evaluation. *Am J Sports Med* 2011;39(7):1487–93.
81. Jackson AT, Drayer NJ, Samona J, et al. Osteochondral allograft transplantation surgery for osteochondral lesions of the talus in athletes. *J Foot Ankle Surg* 2019; 58(4):623–7.
82. Kennedy JG, Murawski CD. The treatment of osteochondral lesions of the talus with autologous osteochondral transplantation and bone marrow aspirate concentrate: surgical technique. *Cartilage* 2011;2(4):327–36.
83. Kim YS, Park EH, Kim YC, et al. Factors associated with the clinical outcomes of the osteochondral autograft transfer system in osteochondral lesions of the talus: second-look arthroscopic evaluation. *Am J Sports Med* 2012;40(12):2709–19.
84. Lee CH, Chao KH, Huang GS, et al. Osteochondral autografts for osteochondritis dissecans of the talus. *Foot Ankle Int* 2003;24(11):815–22.
85. Leumann A, Valderrabano V, Wiewiorski M, et al. Bony periosteum-covered iliac crest plug transplantation for severe osteochondral lesions of the talus: a modified mosaicplasty procedure. *Knee Surg Sports Traumatol Arthrosc* 2014;22(6): 1304–10.
86. Mercer NP, Samsonov AP, Dankert JF, et al. Outcomes of autologous osteochondral transplantation with and without extracellular matrix cartilage allograft augmentation for osteochondral lesions of the talus. *Am J Sports Med* 2022;50(1):162–9.
87. Paul J, Sagstetter M, Lammle L, et al. Sports activity after osteochondral transplantation of the talus. *Am J Sports Med* 2012;40(4):870–4.
88. Shi W, Yang S, Xiong S, et al. Comparison of autologous osteoperiosteal and osteochondral transplantation for the treatment of large, medial cystic osteochondral lesions of the talus. *Am J Sports Med* 2022;50(3):769–77.
89. Valderrabano V, Leumann A, Rasch H, et al. Knee-to-ankle mosaicplasty for the treatment of osteochondral lesions of the ankle joint. *Am J Sports Med* 2009; 37(1_suppl): 105S–11S.
90. Yang S, Jing L, Chen L, et al. Favourable clinical, arthroscopic and radiographic outcomes after autologous osteoperiosteal transplantation for massive medial cystic osteochondral defects of the talus. *Knee Surg Sports Traumatol Arthrosc* 2023;31(8):3509–16.
91. Zhu Y, Xu X. Osteochondral autograft transfer combined with cancellous allografts for large cystic osteochondral defect of the talus. *Foot Ankle Int* 2016; 37(10):1113–8.



ISAKOS
CONGRESS
2025



MUNICH
GERMANY
June 8–11

